The same applies to small molecule inhibitors directed against targets in solid tumors, e.g. the epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib to treat non-small cell lung cancer and the vascular endothelial growth factor receptor (VEGFR) kinase inhibitor sorafenib against renal cancer [14–16]. This evidence concerns the gene EGFR and renal carcinoma.